Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the final results of FUTURE, a phase II umbrella trial designed to explore whether the subtyping-ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yin, Zhu, Xiu-Zhi, Xiao, Yi, Wu, Song-Yang, Zuo, Wen-Jia, Yu, Qiang, Cao, A-Yong, Li, Jun-Jie, Yu, Ke-Da, Liu, Guang-Yu, Wu, Jiong, Sun, Tao, Cui, Jiu-Wei, Lv, Zheng, Li, Hui-Ping, Zhu, Xiao-Yu, Jiang, Yi-Zhou, Wang, Zhong-Hua, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156707/
https://www.ncbi.nlm.nih.gov/pubmed/36973538
http://dx.doi.org/10.1038/s41422-023-00795-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156707/
https://www.ncbi.nlm.nih.gov/pubmed/36973538
http://dx.doi.org/10.1038/s41422-023-00795-2

Ejemplares similares